Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936037 | 0.98 | GSK3B (0.44) | RAB9AGSK3BKMT2AMEN1LMNA | |
| Bromide SCHEMBL3847336 | 0.85 | NPC1 (0.42) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL2947798 | 0.85 | RAB9A (0.46) | RAB9AGSK3BKMT2ALMNASMN1; SMN2 | |
| Bromide SCHEMBL122634 | 0.84 | ALDH1A1 (0.43) | RAB9AGSK3BKMT2AMEN1LMNA | |
| Bromide SCHEMBL7402289 | 0.84 | ALDH1A1 (0.43) | RAB9AGSK3BKMT2AMEN1LMNA | |
| SCHEMBL6935144 | 0.83 | GSK3B (0.44) | RAB9AGSK3BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL7074124 | 0.83 | NPC1 (0.43) | RAB9AKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4019649 | 0.81 | ALDH1A1 (0.43) | RAB9AGSK3BKMT2AMEN1LMNA | |
| Bromide SCHEMBL3853720 | 0.81 | ALDH1A1 (0.55) | RAB9AGSK3BKMT2AMEN1LMNA | |
| SCHEMBL8390047 | 0.79 | ALDH1A1 (0.52) | RAB9AGSK3BKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | CERAMI ANTHONY | 2008-06-05 | — | — | US | disclosed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20020193412-A1 | Compounds and compositions for treating tissue ischemia | TRACEY KEVIN J (US) | 2002-12-19 | — | — | US | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | disclosed |
| EP-0808163-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996022095-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193412-A1 | Compounds and compositions for treating tissue ischemia | TNNI3, ABAT, ALDH7A1 | RAB9A 4611/4885GSK3B 69/4885KMT2A 3340/4885 |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | RAB9A 3134/4885GSK3B 300/4885KMT2A 3186/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | RAB9A 1586/4885GSK3B 604/4885KMT2A 2711/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | RAB9A 2313/4885GSK3B 3887/4885KMT2A 4535/4885 |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | RAB9A 3798/4885GSK3B 1564/4885KMT2A 3856/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | RAB9A 3660/4885GSK3B 3019/4885KMT2A 4545/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | RAB9A 3397/4885GSK3B 2713/4885KMT2A 4493/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | RAB9A 3572/4885GSK3B 2905/4885KMT2A 4326/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | RAB9A 3838/4885GSK3B 1229/4885KMT2A 3689/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | RAB9A 4074/4885GSK3B 3150/4885KMT2A 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.